RSS-Feed abonnieren

DOI: 10.1055/s-0043-1775818
Prevalence and Pattern of Nodal Metastases in Ovarian Malignancy: A Perioperative Audit
Autor*innen
Abstract
It is still unclear whether or not full nodal dissection and detailed staging offer any benefits. Little is known regarding the degree of nodal involvement based on histotype. We aimed to assess the lymphatic dissemination patterns and prevalence in early-stage epithelial ovarian cancer and identify the underlying risk factors for nodal metastases. This is a prospective study conducted over a period of three years. Institutional ethics committee approval has been obtained. A total of 157 consecutive patients with apparently early-stage ovarian cancer, who were treated at the Department of Gynecologic Oncology, Acharya Harihar Post Graduate Institute of Cancer (AHPGIC) from January 2020 to January 2023, were included. The most frequent grade was 3 (66.8%), and the most common histotype was high-grade serous ovarian cancer (HGSOC; 55.4%), followed by mucinous (16.5%) and endometrioid (14.01%) varieties. Seromucinous and clear cell ovarian cancers were found infrequently. The most common pattern was isolated pelvic nodal involvement in 48.9% of patients, followed by both para-aortic and pelvic nodal involvement in 25.5% of patients; 13 patients had isolated para-aortic nodal involvement. HGSOC was most commonly associated with isolated metastasis to the pelvic lymph nodes alone, while the endometrioid variety was prone to both pelvic and para-aortic spread. Out of the 55 patients with nonserous tumors, 12.72% exhibited nodal involvement. Most nonserous tumors showed affinity for both pelvic and para-aortic (42.85%) nodal metastases. Only grade 3 and serous histology showed a positive association with nodal metastasis. Approximately 45.2% of cases showed upstaging after surgical staging procedures. Multicentric studies are essential to analyze the prognostic impact of systematic lymphadenectomy in ovarian carcinoma patients, depending on the histotype and distribution pattern of nodal metastases.
Keywords
lymph node metastases - ovarian cancers - serous tumors - nonserous tumors - pelvic nodes - para-aortic lymph nodePublikationsverlauf
Artikel online veröffentlicht:
13. Oktober 2023
© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Morice P, Joulie F, Camatte S. et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 2003; 197 (02) 198-205
- 2 Le T, Adolph A, Krepart GV, Lotocki R, Heywood MS. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 2002; 85 (02) 351-355
- 3 Ayhan A, Gultekin M, Taskiran C. et al. Lymphatic metastasis in epithelial ovarian carcinoma with respect to clinicopathological variables. Gynecol Oncol 2005; 97 (02) 400-404
- 4 Vergote I. Prognostic factors in stage I ovarian carcinoma. Verh K Acad Geneeskd Belg 2001; 63 (03) 257-271 , discussion 272–276
- 5 Young RC, Walton LA, Ellenberg SS. et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322 (15) 1021-1027
- 6 Hoskins W. et al. In: Principles and practice of gynecologic oncology. 4th ed.. Philadelphia: Lippincott Williams and Wilkins; 2005
- 7 Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. New England Journal of Medicine 2019; Feb 28 380 (09) 822-32
- 8 Chan JK, Munro EG, Cheung MK. et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 2007; 109 (01) 12-19
- 9 Chan JK, Kapp DS, Cheung MK. et al. The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients. Br J Cancer 2007; 97 (05) 605-611
- 10 Aletti GD, Dowdy S, Podratz KC, Cliby WA. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. Am J Obstet Gynecol 2006; 195 (06) 1862-1868
- 11 Onda T, Yoshikawa H, Yasugi T. et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. Cancer 1998; 83 (08) 1555-1560
- 12 Maggioni A, Benedetti Panici P, Dell'Anna T. et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006; 95 (06) 699-704
- 13 Husband JE. CT/MRI of nodal metastases in pelvic cancer. Cancer Imaging 2002; 2 (02) 123-129
- 14 Ganeshalingam S, Koh DM. Nodal staging. Cancer Imaging 2009; 9 (01) 104-111
- 15 Suzuki M, Ohwada M, Yamada T, Kohno T, Sekiguchi I, Sato I. Lymph node metastasis in stage I epithelial ovarian cancer. Gynecol Oncol 2000; 79 (02) 305-308
- 16 Benedetti-Panici P, Greggi S, Maneschi F. et al. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol 1993; 51 (02) 150-154
- 17 Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991; 40 (02) 103-106
- 18 Panici PB, Maggioni A, Hacker N. et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005; 97 (08) 560-566
- 19 Takeshima N, Hirai Y, Umayahara K, Fujiwara K, Takizawa K, Hasumi K. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. Gynecol Oncol 2005; 99 (02) 427-431
- 20 Cass I, Li AJ, Runowicz CD. et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 2001; 80 (01) 56-61
- 21 Petru E, Lahousen M, Tamussino K. et al. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 1994; 170 (02) 656-662
- 22 Trimbos JB, Vergote I, Bolis G. et al; EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003; 95 (02) 113-125
- 23 Morice P, Joulie F, Rey A. et al. Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy. Eur J Gynaecol Oncol 2004; 25 (02) 169-174
- 24 He M, Lai Y, Peng H, Tong C. Role of lymphadenectomy during interval debulking surgery performed after neoadjuvant chemotherapy in patients with advanced ovarian cancer. Front Oncol 2021; 11: 646135
